We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+38.9%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.13B
AUM Growth
+$1.33B
Cap. Flow
+$252M
Cap. Flow %
3.09%
Top 10 Hldgs %
38.33%
Holding
153
New
32
Increased
35
Reduced
44
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$111M
3
ESRX
Express Scripts Holding Company
ESRX
+$60.7M
4
ABBV icon
AbbVie
ABBV
+$52.2M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$48.2M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$78.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$61.6M
3
CELG
Celgene Corp
CELG
+$61.1M
4
INCY icon
Incyte
INCY
+$58.6M
5
UNH icon
UnitedHealth
UNH
+$51.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.16%
2 Technology 0.09%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOMA
76
DELISTED
Xoma
XOMA
$12.7M 0.16%
121,850
-19,631
-14% -$2.85M
NUVA
77
DELISTED
NuVasive, Inc.
NUVA
$12.1M 0.15%
+316,000
New +$11.6M
ALIM
78
DELISTED
Alimera Sciences
ALIM
$11.8M 0.15%
+100,000
New +$9.71M
SVA
79
DELISTED
Sinovac Biotech, Ltd
SVA
$11.8M 0.15%
1,637,500
– –
PTX
80
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$11.8M 0.14%
219,850
-12,230
-5% -$404K
ARQL
81
DELISTED
Arqule Inc
ARQL
$11.7M 0.14%
5,702,000
– –
LAB icon
82
CALL
Standard BioTools
LAB
$311M
$11.4M 0.14%
+100,000
New +$4.4M
VRTX icon
83
Vertex Pharmaceuticals
VRTX
$124B
$11.3M 0.14%
160,000
-95,000
-37% -$7.52M
MRGE
84
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$11.3M 0.14%
4,628,500
– –
ATRS
85
DELISTED
Antares Pharma, Inc.
ATRS
$11.2M 0.14%
3,213,900
-1,378,100
-30% -$6.11M
NSPR icon
86
InspireMD
NSPR
$32.1M
$10.4M 0.13%
1
– –
EXEL icon
87
Exelixis
EXEL
$14.2B
$10.2M 0.13%
2,888,000
-6,501,000
-69% -$44.3M
CFN
88
CALL
DELISTED
CAREFUSION CORPORATION
CFN
$10.1M 0.12%
+250,000
New +$10.1M
DVA icon
89
DaVita
DVA
$15.4B
$9.85M 0.12%
143,000
– –
VTRS icon
90
CALL
Viatris
VTRS
$20.8B
$9.77M 0.12%
+200,000
New +$9.71M
XNCR icon
91
Xencor
XNCR
$1.48B
$9.4M 0.12%
801,700
+99,100
+14% +$1.04M
AEGR
92
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$9.24M 0.11%
+200,000
New +$11.7M
AEGR
93
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
$9.24M 0.11%
+200,000
New +$11.7M
GEVA
94
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$9.22M 0.11%
111,100
-18,900
-15% -$1.75M
RDHL
95
Redhill Biopharma
RDHL
$4.44M
$8.9M 0.11%
+632
New +$8.47M
FRX
96
DELISTED
FOREST LABORATORIES INC
FRX
$8.67M 0.11%
94,000
-45,000
-32% -$3.63M
UNH icon
97
UnitedHealth
UNH
$389B
$8.36M 0.1%
102,000
-689,000
-87% -$51.9M
VIRX
98
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.93M 0.1%
+5,714
New +$6.64M
PRGO icon
99
CALL
Perrigo
PRGO
$1.43B
$7.73M 0.1%
50,000
-125,000
-71% -$19.7M
VNDA icon
100
Vanda Pharmaceuticals
VNDA
$310M
$7.51M 0.09%
462,400
-527,600
-53% -$7.5M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2014 Portfolio in Review

As of Q1 2014, OrbiMed held 153 positions worth $8.13B, up 20% from $6.8B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $252M of net new capital in Q1 2014, opening 32 new positions and adding to 35 existing holdings. Its largest new stake was Eli Lilly: 543,000 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $78.6M trimmed.

  • OrbiMed's largest Q1 2014 buy was Eli Lilly: 543,000 shares worth $32M.
  • OrbiMed added most to Allergan Inc in Q1 2014, an estimated $182M increase.
  • OrbiMed's biggest Q1 2014 reduction was Aetna Inc, cutting an estimated $78.6M.
  • OrbiMed fully exited QIAGEN NV in Q1 2014, selling an estimated $45.9M.
  • OrbiMed's ten largest holdings make up 38% of its $8.13B portfolio in Q1 2014.
  • OrbiMed opened 32 new positions and closed 13 in Q1 2014.
  • OrbiMed's portfolio value rose 20% quarter-over-quarter to $8.13B.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.